This volume provides the current understanding of death receptor's TLR3 signaling regulation in
cancer. Death receptors including TRAIL-R1 TRAIL-R2 Fas and TNF-RI owing to their ability
to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system
have been considered to variable extent as important therapeutic targets for cancer therapy.
But an increasing body of evidence suggests that some of these receptors may also contribute to
tumorigenesis or that new players such as TLR3 may be targeted for cancer therapy due to their
ability to behave like death receptors.
